Policies and practices have proliferated to optimize prescribers’
use of their states’ prescription drug monitoring programs, which are
statewide databases of controlled substances dispensed at retail pharmacies. Our
study assessed the effectiveness of three such policies: comprehensive
legislative mandates to use the program, laws that allow prescribers to delegate
its use to office staff, and state participation in interstate data sharing. Our
analysis of information from a large commercial insurance database indicated
that comprehensive use mandates implemented during 2011–15 were
associated with a 6–9 percent reduction in opioid prescriptions with high
risk for misuse and overdose. We also found delegate laws to be associated with
reductions of a similar magnitude for selected outcomes. In general, the effects
of all three policies strengthened over time, especially beginning in the second
year after implementation. Our findings support comprehensive use mandates and
delegate laws to optimize prescribers’ use of drug monitoring programs,
but the results will need updates in the context of evolving state opioid
policies—including the increasing integration of drug monitoring data
with electronic health records.
Background:
Not enough evidence exists to compare buprenorphine–naloxone with extended-release naltrexone for treating opioid use disorder.
Objective:
To evaluate the relative cost-effectiveness of buprenorphine–naloxone versus extended-release naltrexone.
Design:
Cost-effectiveness analysis alongside a previously reported randomized clinical trial of 570 adults in 8 U.S. inpatient or residential treatment programs.
Data Sources:
Study instruments.
Target Population:
Adults with opioid use disorder.
Time Horizon:
24-week intervention with an additional 12 weeks of observation.
Perspective:
Health care sector and societal.
Interventions:
Buprenorphine–naloxone and extended-release naltrexone.
Outcome Measures:
Incremental costs combined with incremental quality-adjusted life-years (QALYs) and incremental time abstinent from opioids.
Results of Base-Case Analysis:
Use of the health care sector perspective and a willingness-to-pay threshold of $100 000 per QALY showed buprenorphine–naloxone to be preferable to extended-release naltrexone in 97% of bootstrap replications at 24 weeks and in 85% at 36 weeks. Similar results were obtained with incremental time abstinent from opioids as an outcome and with use of the societal perspective.
Results of Sensitivity Analysis:
The base-case results were sensitive to the cost of the 2 treatments and the success of randomized treatment initiation.
Limitation:
Relatively short follow-up for a chronic condition, substantial missing data, no information on patient out-of-pocket and social service costs.
Conclusion:
Buprenorphine–naloxone is preferred to extended-release naltrexone as first-line treatment when both options are clinically appropriate and patients require detoxification before initiating extended-release naltrexone.
Objective
To estimate the own‐price elasticity of demand for naloxone, a prescription medication that can counter the effects of an opioid overdose, and predict the change in pharmacy sales following a conversion to over‐the‐counter status.
Data Sources/Study Setting
The primary data source was a nationwide prescription claims dataset for 2010‐2017. The data cover 80 percent of US retail pharmacies and account for roughly 90 percent of prescriptions filled. Additional covariates were obtained from various secondary data sources.
Study Design
We estimated a longitudinal, simultaneous equation model of naloxone supply and demand. Our primary variables of interest were the quantity of naloxone sold, measured as total milligrams sold at pharmacies, and the out‐of‐pocket price paid per milligram, both measured per ZIP Code and quarter‐year.
Data Collection/Extraction Methods
Primary data came directly from payers and processors of prescription drug claims.
Principal Findings
We found that, on average, a 1 percent increase in the out‐of‐pocket price paid for naloxone would result in a 0.27 percent decrease in pharmacy sales. We predict that the total quantity of naloxone sold in pharmacies would increase 15 percent to 179 percent following conversion to over‐the‐counter status.
Conclusions
Naloxone is own‐price inelastic, and conversion to over‐the‐counter status is likely to lead to a substantial increase in total pharmacy sales.
Long-acting formulation, high daily dosage, and longer duration of the first opioid prescription were each associated with increased high-risk use of opioids in the long term.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.